Overall, the parallel between this more complete Ts65Dn DS model and the monogenic Dyrk1a overexpression model highlights the complexity of the physiological and pathological mechanisms responsible for the neurocognitive symptoms of DS and underscores the importance of exploring new therapeutic strategies other than targeting DYRK1A activity. The gene discussed is DYRK1A; the disease is Dravet syndrome.